… An official American Thoracic Society workshop report: use of animal models for the preclinical
assessment of potential therapies for pulmonary fibrosis. Am J Respir Cell Mol Biol 2017; …

… Inhibition of this TGFβ1–HIF1α–PDK1 axis by genetic deletion of HIF1α or by drug-mediated
inhibition of PDK1 using dichloroacetate reduces pulmonary fibrosis 61,62 . Additionally, in …

Idiopathic pulmonary fibrosis (IPF) is a fibroproliferative disorder limited to the lung. New
findings, starting from our proteomics studies on IPF, suggest that systemic involvement with …

… The antiparasitic agent ivermectin may be another therapeutic approach worth exploring
further. In an in vitro study, it showed a 99.98% reduction in viral load after 48 h of treatment, in …

… treatment of idiopathic pulmonary fibrosis. Pirfenidone has … therapy, investigators have turned
to therapeutic approaches … as a form of cardiac therapy initially emerged in animal studies …

… Oxidative stress has been associated with a number of human fibrotic diseases, including
idiopathic pulmonary fibrosis (IPF). Although oxidative stress is associated with both fibrosis …

… Arguing against this therapeutic approach, however, are recent reports indicating that anti–PD-1
immunotherapy can cause interstitial lung disease through an unclear mechanism (97). …

… This study suggests that chronic inhibition of Arg-1 may represent a potential therapeutic
approach; however, studies in other cell lines have shown poor outcomes, including worsened …

… On this basis, inhibition of TGF-β and its activity has great therapeutic potential for the
treatment of various fibrotic diseases such as pulmonary fibrosis, renal fibrosis, systemic sclerosis …

… fibrosis. Decreasing the mechanical tension on alveoli could be a therapeutic approach for
treating progressive lung fibrosis … pulmonary fibrosis (IPF), 18 patients with chronic obstructive …